Why REGENXBIO Inc.’s (RGNX) Stock Is Up 8.68%
As of Friday, August 21, REGENXBIO Inc.’s RGNX share price has surged by 8.68%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why REGENXBIO Inc.’s (RGNX) Stock Is Up 6.50%
As of Wednesday, August 19, REGENXBIO Inc.’s RGNX share price has surged by 6.50%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Is REGENXBIO Inc. (RGNX) Overvalued?
We dive into why REGENXBIO Inc. (RGNX) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Michael Rose
Why REGENXBIO Inc.’s (RGNX) Stock Is Up 5.07%
As of Wednesday, August 12, REGENXBIO Inc.’s RGNX share price has surged by 5.07%, which has investors questioning if this is right time to sell.Michael Rose
Why REGENXBIO Inc.’s (RGNX) Stock Is Down 6.21%
As of Friday, August 07, REGENXBIO Inc.’s RGNX share price has dipped by 6.21%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $707.7 | $292.6 | 40% |
|
| Shares Out (Mil) | 53.0 | 54.4 | 49% |
|
| Institutional Ownership | 89.9% | 93.2% | 57% |
|
| Float (Mil) | 57.3 | 40.2 | 50% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 911 | 544 | 69% |
|
| Price Change (52-week) |
32.8% | 59.7% | 70% |
|
| Growth | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.0% | 13.6% | 23% |
|
| Net Income (5yr) | (11.7%) | (10.1%) | 28% |
|
| EPS (5yr) | (4.7%) | 16.0% | 25 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.6%) | (15.6%) | 48% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($1.268) | ($3.430) | ($2.312) | |
| Month Ago EPS | ($0.967) | ($2.791) | ($2.543) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($1.482) | ($2.849) | ($2.521) | |
| Year/Year Chg | (394.9%) | (8.8%) | (45.4%) | |
| Financials | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $175 | $37 | 31% |
|
| Net Income (TTM) (Mil) | ($196) | ($43) | 7% |
|
| EPS (TTM) | ($3.765) | ($1.400) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($247) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | ($43) | $2 | 20% |
|
| Long-Term Debt (Q1) (Mil) | $216 | $4 | 51% |
|
| Enterprise Value (Q1) (Mil) | na | $164 | na |
|
| Valuation | RGNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.12 | 2.83 | 87% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | RGNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (44.9%) | 64.2% | 2% |
|
| Net Margin | (112.6%) | (75.9%) | 7% |
|
| ROA | (40.6%) | (47.5%) | 14% |
|
| ROE | (137.6%) | (55.0%) | 6% |
|
| Liabilities to Assets | 81.4% | 29.6% | 76% |
|
| F-Score | 3 | 3 | 18% |
|
REGENXBIO Inc. did not pass any screens on 8/21/2026.
